China Universal Asset Management Co. Ltd. Has $1.15 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

China Universal Asset Management Co. Ltd. raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 32.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,749 shares of the company's stock after purchasing an additional 676 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in IDEXX Laboratories were worth $1,154,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IDXX. MorganRosel Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the 1st quarter worth about $26,000. Hurley Capital LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at approximately $29,000. Rialto Wealth Management LLC bought a new position in IDEXX Laboratories in the 4th quarter worth approximately $30,000. Colonial Trust Co SC increased its position in IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after buying an additional 39 shares during the period. Finally, Itau Unibanco Holding S.A. increased its position in IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after buying an additional 81 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on IDXX. Morgan Stanley lifted their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Jefferies Financial Group started coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target on the stock. Leerink Partners boosted their price target on IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. Stifel Nicolaus boosted their price target on IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a research note on Wednesday, July 2nd. Finally, Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $558.11.

IDEXX Laboratories Trading Down 1.2%

Shares of IDXX stock traded down $6.72 on Tuesday, reaching $538.84. 485,932 shares of the stock were exchanged, compared to its average volume of 645,509. The stock has a market cap of $43.33 billion, a PE ratio of 49.80, a P/E/G ratio of 3.99 and a beta of 1.54. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $579.02. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.16 and a quick ratio of 0.81. The stock has a 50 day moving average price of $512.86 and a 200 day moving average price of $456.11.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The firm's quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.71 earnings per share. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the sale, the director owned 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.